Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study.
Marcello PersicoAndrea AglittiMichele MilellaCarmine CoppolaVincenzo MessinaErnesto ClaarIvan GentileFernando SogariPaola PierriLorenzo A SuraceFilomena MoriscoPaolo TundoGiuseppina BrancaccioGaetano ServiddioPietro GattiAntonio P TermiteGiovan G Di CostanzoBenedetto CaroleoRaffaele CozzolongoNicola CoppolaAnnamaria LongoLuca FontanellaAlessandro FedericoValerio RosatoIrene TerrenatoMario MasaronePublished in: Liver international : official journal of the International Association for the Study of the Liver (2019)
The MISTRAL study provides evidence of GLE/PIB efficacy in a field-practice scenario in a highly epidemic HCV area in southern Italy; it unveiled significant differences in genotype distribution among the most underserved and difficult-to-treat patient subgroups including PWID.